Full Press Release Details
Precipio Announces Q4 2017 Revenue at
350% of Previous Quarter
First post-merger quarter to turn the corner and demonstrate
NEW HAVEN, CT, (February 9th, 2018) - Specialty
diagnostics company Precipio, Inc. (NASDAQ:PRPO), announces preliminary, unaudited revenues for the 4th quarter of 2017
of approximately $945,000, representing three-fold from the previous quarter of approximately $270,000, as well as a three-fold
year-over-year from the 4th quarter of 2016 revenues of approximately $316,000.
2017 Business Integration; 2018 Sales Acceleration
Following the merger with Transgenomic, Inc. in June 2017, we
undertook the task of relocating Transgenomic's laboratory operations to Precipio's New Haven location, which was completed
within 90 days, by the end of the 3rd quarter of 2017. In early October, following a successful migration of all operations,
and the training of the necessary staff, Precipio announced the re-opening of its CLIA operations in New Haven. When we resumed
operations in October 2017, we were able to retain all customers and quickly refocus on business growth.
"Now that assets have been integrated and systems optimized,
we have resumed our focus on sales growth and aggressively capturing market share with our disruptive diagnostic products and services,"
commented Ilan Danieli, CEO. "Our team worked around the clock to ensure resumption of services within Q3-2017, and our sales
growth in Q4 reflects that hard work. We will remain completely focused on continuing this revenue growth throughout the year."
Revenue Composition & ICP potential
The majority of revenue was generated by our pathology diagnostic
services and various pharma projects handled in our laboratory. Our first ICE-COLD PCR (ICP) kit was launched mid-way through
Q4-2017, as previously announced, and we were able to quickly convert those products into new customers and revenue.
Although ICP kit sales made up less than 5% of the revenue for
this quarter, with our customer, product, and platform expansion, we expect ICP to drive and contribute a significantly larger
share of our revenue by year end.
Precipio's ICP kit, our mutation enrichment technology
for liquid biopsies, leads to better cancer outcomes due to the ability to cost effectively test and monitor patients using a simple
blood draw instead of an invasive tissue sample. Patients can be frequently tested and monitored for genetic mutations, which may
provide an immediate and critical indication of possible treatment responses.
As we continue to release additional ICP panels into the market,
those tests will also be available in our CLIA laboratory for direct ordering by physicians and hospitals. Many such hospitals
don't have the necessary facilities to bring those tests in-house, yet they would like to monitor their patients in a rapid,
cost-effective manner to identify genetic changes that can help those physicians manage their patient's treatment.
These customers will be able to now send those tests to Precipio's
CLIA laboratory for immediate and rapid testing and results, generating an additional revenue stream.
Our multi-pronged solution enables hospitals of any size, located
anywhere in the world, to either on-board these tests in-house, or use our laboratory to run tests on liquid biopsies, and provide
them with this critical information.
Furthermore, we believe that with the increased variability
of platforms upon which ICP can be utilized (including Next Generation Sequencing), other segments such as pharmaceutical and clinical
trial customers (such as CROs) will become substantial potential users of ICP within their business, generating additional revenue
from the continuous commercialization of ICP.
Precipio has built a platform designed
to eradicate the problem of misdiagnosis by harnessing the intellect, expertise and technology developed within academic institutions
and delivering quality diagnostic information to physicians and their patients worldwide. Through its collaborations with world-class
academic institutions specializing in cancer research, diagnostics and treatment, initially the Yale School of Medicine, Precipio
offers a new standard of diagnostic accuracy enabling the highest level of patient care. For more information, please visit www.precipiodx.com.
The financial data for the quarter ended December 31, 2017 set
forth above is preliminary and is based on information available to management as of the date of this press release and is subject
to completion by management of Precipio's financial statements for the quarter and year ended December 31, 2017. Precipio's
independent registered public accountants have not audited, reviewed or performed any procedures with respect to such preliminary
financial data and accordingly do not express an opinion or any other form of assurance with respect thereto.
Forward-Looking Statements
Certain statements in this press release constitute "forward-looking
statements," within the meaning of federal securities laws, including statements related to ICP technology, including expected
revenue for the quarter ended December 31, 2017, expected composition of revenue in 2017 and 2017, other financial projections
and potential market opportunity, plans and prospects and other statements containing the words "anticipate," "intend,"
"may," "plan," "predict," "will," "would," "could," "should,"
and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform
Act of 1995. The Company's actual results could differ materially from those anticipated in these forward-looking statements as
a result of various factors. Factors that could cause future results to materially differ from the
recent results or those projected in forward-looking statements include the known risks, uncertainties and other factors described
in the Company's definitive proxy statement filed on May 12, 2017, the Company's Quarterly Report on Form 10-Q for
the quarter ended September 30, 2017, the Company's prior filings and from time to time in the Company's subsequent
filings with the Securities and Exchange Commission. Any change in such factors, risks and uncertainties may cause the actual
results, events and performance to differ materially from those referred to in such statements. All information in this press
release is as of the date of the release and the Company does not undertake any duty to update this information, including any
forward-looking statements, unless required by law.